Difference between revisions of "Nitric oxide"
| Line 3: | Line 3: | ||
| drug_class = | | drug_class = | ||
| drug_class_color = | | drug_class_color = | ||
| uses = | | uses = Pulmonary HTN; RHF | ||
| contraindications = | | contraindications = severe LHF; R to L shunt | ||
| routes = | | routes = Inhalational | ||
| dosage = | | dosage = 1-20 ppm (parts per million) | ||
| mechanism = | |||
| adverse_effects = | |||
| time_onset = | |||
| duration = | |||
| metabolism = | |||
| halflife_redistribution = | |||
| halflife_elimination = | |||
| clearance = | |||
| protein_binding = | |||
}} | }} | ||
| Line 14: | Line 23: | ||
* Pulmonary HTN | * Pulmonary HTN | ||
* Right ventricular failure | * Right ventricular failure | ||
| Line 20: | Line 28: | ||
=== Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. --> === | === Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. --> === | ||
* Severe left heart dysfunction | |||
* Congenital heart conditions with dependent right to left shunt (e.g. interrupted aortic arch, critical aortic stenosis, hypoplastic left heart syndrome), which would shunt blood away from systemic circulation toward pulmonary circulation | |||
=== Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> === | === Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> === | ||
Latest revision as of 19:05, 30 August 2021
| Clinical data | |
| Uses |
Pulmonary HTN; RHF |
|---|---|
| Contraindications |
severe LHF; R to L shunt |
| Routes of administration |
Inhalational |
| Dosage |
1-20 ppm (parts per million) |
| Pharmacodynamics | |
| Pharmacokinetics | |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Nitric oxide (NO) is a naturally occurring endothelial-derived vasodilator that exhibits most of its vasodilatory effects in the pulmonary vasculature.[1] It is frequently indicated for patients with right heart failure and hypoxemia. It exists as a colorless odorless gas, and is administered inhalationally.
Uses
- Pulmonary HTN
- Right ventricular failure
Contraindications
Absolute contraindications
- Severe left heart dysfunction
- Congenital heart conditions with dependent right to left shunt (e.g. interrupted aortic arch, critical aortic stenosis, hypoplastic left heart syndrome), which would shunt blood away from systemic circulation toward pulmonary circulation
Precautions
Pharmacology
Pharmacodynamics
Mechanism of action
Nitric oxide diffuses to smooth muscle of pulmonary vasculature -> activates soluble guanylate cyclase (sGC) -> converts GTP to cGMP -> activates protein kinase G -> increases Ca2+ reuptake -> decreased calcium decreasing myosin phosphorylation -> relaxation of smooth muscle.
Adverse effects
Pharmacokinetics
Chemistry and formulation
History
Initially discovered in 1987. Won Nobel Prize in Physiology and Medicine in 1998.
References
- ↑ Ichinose, Fumito; Roberts, Jesse D.; Zapol, Warren M. (2004-06-29). "Inhaled Nitric Oxide". Circulation. 109 (25): 3106–3111. doi:10.1161/01.CIR.0000134595.80170.62.
Top contributors: Tony Wang